Modulation of faecal metagenome in Crohn’s disease: Role of microRNAs as biomarkers

María Rojas-Feria, Teresa Romero-García, Josef Ángel Fernández Caballero-Rico, Helena Pastor Ramírez, Marta Avilés-Recio, Manuel Castro-Fernandez, Natalia Chueca Porcuna, Manuel Romero-Gómez, Federico García, Lourdes Grande, José A Del Campo

Institutional review board statement: The study was reviewed and approved by the Institutional Review Board of Valme Hospital of Seville University.

Conflict-of-interest statement: All authors declare there are no competing interests in this study.

Data sharing statement: All data regarding this manuscript will be available upon request.

ARRIVE guidelines statement: The manuscript was prepared according to the ARRIVE Guidelines.

Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

Manuscript source: Invited manuscript

Corresponding author to: José A Del Campo, PhD, Senior Scientist, Department of Digestive Diseases, Valme University Hospital, UGC Digestive Disease and CIBERehd, Servicio Andaluz de Salud, Avda. Bellavista s/n, Sevilla E-41014, Spain. jantonio.delcampo@ciberehd.org

Telephone: +34-95-5015485

Received: September 19, 2018
Peer-review started: September 19, 2018
First decision: November 1, 2018
Revised: November 13, 2018
Accepted: November 16, 2018
Article in press: November 16, 2018
Published online: December 14, 2018
Abstract

BACKGROUND
The gut microbiota plays a key role in the maintenance of intestinal homeostasis and the development and activation of the host immune system. It has been shown that commensal bacterial species can regulate the expression of host genes. 16S rRNA gene sequencing has shown that the microbiota in inflammatory bowel disease (IBD) is abnormal and characterized by reduced diversity. MicroRNAs (miRNAs) have been explored as biomarkers and therapeutic targets, since they are able to regulate specific genes associated with Crohn’s disease (CD). In this work, we aim to investigate the composition of gut microbiota of active treatment-naïve adult CD patients, with miRNA profile from gut microbiota.

AIM
To investigate the composition of gut microbiota of active treatment-naïve adult CD patients, with miRNA profile from gut microbiota.

METHODS
Patients attending the outpatient clinics at Valme University Hospital without relevant co-morbidities were matched according to age and gender. Faecal samples of new-onset CD patients, free of treatment, and healthy controls were collected. Faecal samples were homogenized, and DNA was amplified by PCR using primers directed to the 16S bacterial rRNA gene. Pyrosequencing was performed using GS-Junior platform. For sequence analysis, MG-RAST server with the database Ribosomal Project was used. MiRNA profile and their relative abundance were analyzed by quantitative PCR.

RESULTS
Microbial community was characterized using 16S rRNA gene sequencing in 29 samples (n = 13 CD patients, and n = 16 healthy controls). The mean Shannon diversity was higher in the healthy control population compared to CD group (5.5 vs 3.7). A reduction in Firmicutes and an increase in Bacteroidetes were found. Clostridia class was also significantly reduced in CD. Principal components analysis showed a grouping pattern, identified in most of the subjects in both groups, showing a marked difference between control and CD groups. A functional metabolic study showed that a lower metabolism of carbohydrates (P = 0.000) was found in CD group, while the metabolism of lipids was increased. In CD patients, three miRNAs were induced in affected mucosa: mir-144 (6.2 ± 1.3 fold), mir-519 (21.8 ± 3.1) and mir-211 (2.3 ± 0.4).

CONCLUSION
Changes in microbial function in active non-treated CD subjects and three miRNAs in affected vs non-affected mucosa have been found. miRNAs profile may serve as a biomarker.

Key words: Crohn’s disease; Dysbiosis; microRNAs; Firmicutes; Bacteroidetes

© The Author(s) 2018. Published by Baishideng Publishing Group Inc. All rights reserved.

Core tip: In this study, we have found a shift in microbial gut community composition that supports dysbiosis in Crohn’s disease (CD) patients. The greatest interest of our work is that we have only included new-onset adult CD patients. We found that active non-treated CD patients had a low Firmicutes/Bacteroidetes ratio, less biodiversity in the structure of microbial communities and a significantly different pattern on gut microbiota distribution. Three microRNAs (miRNAs) have been found induced in affected mucosa vs non-affected mucosa in CD, indicating that miRNA profile may serve as biomarker for active disease.
diseases\textsuperscript{[56]}. Epigenetic can be defined as heritable changes in gene function not explained by changes in DNA sequence. One of the main epigenetic mechanisms includes RNA interference, transmitted by microRNAs (miRNAs). MiRNAs are noncoding single stranded RNAs that regulate gene expression at the posttranscriptional level, influencing numerous biological processes, as cell proliferation, differentiation and death. A large number of miRNAs (> 1600) has been described in humans. Each miRNA can regulate multiple genes and a single gene may be targeted by many different miRNA\textsuperscript{[6]}. A challenge is to identify which of the multiple miRNA that regulate a gene has an essential role.

In IBD, research focusing on miRNA did not begin until 2008. Wu et al\textsuperscript{[7]} carried out the first study in which they identified miRNA profile in intestinal biopsies from IBD patients. Since then, and over the last decade, studies related to miRNA have increased exponentially, focusing mainly on three aspects: the alteration of miRNAs in the different IBD profiles, their therapeutic role and their pathway. Likewise, these studies have tried to identify miRNA in different tissues: colon, blood, and saliva\textsuperscript{[8]}; as a goal to find an effective non-invasive test for disease. MiRNAs have been involved in the pathogenesis of IBD and have been explored as biomarkers and therapeutic targets\textsuperscript{[9]}. It has been shown that miRNAs regulate specific genes associated with Crohn’s disease (CD) including nucleotide-binding oligomerization domain-containing protein 2 (NOD2), interleukin-6 (IL)-6 and tumor necrosis factor (TNF).

Cao et al\textsuperscript{[9]} described the role of miRNA on intestinal epithelial barrier deregulation, and disruption of immune homeostasis, leading the development and progression of the disease. Apart from that, miRNAs have been proposed as biomarkers of IBD, useful in differential diagnosis of IBD, and as a tool of treatment evaluation and prognosis\textsuperscript{[10]}.

Identification of host and microbiota alterations in individual patients should lead to selective target interventions. In this study, we first analyzed the faecal microbiota composition in CD patients at the time of diagnosis. Secondly, we compared miRNA expression in CD gut samples obtained from endoscopically normal and affected mucosa, in order to find a marker of active IBD.

**MATERIALS AND METHODS**

**Patients**

Consecutive new-onset adult CD patients, free of treatment, that underwent colonoscopy for diagnostic purposes, were included in this study. Informed consent was obtained from all of them. Faecal samples from 13 patients (9 females, 67%; mean age 32.18 ± 14.8 years old) and 16 healthy controls, matched by age and gender, were also collected. Inflammatory behaviour was present in 77% (10/13) of patients, stenotic in 23% (3/10) and fistulizing in 7.6% (1/13). None of the patients or the controls received antibiotic treatment the 10 wk before of recruitment.

A total of 35 gut biopsy samples from the subset of patients with non-fistulizing non-stenotic phenotype were taken (17 from affected mucosa and 18 from healed mucosa), immediately frozen in liquid nitrogen and submitted for miRNA study. Four patients had ileal, 3 colonic and 3 ileocolonic diseases.

**DNA extraction, quantification and pyrosequencing analysis**

Faecal samples were homogenized in a Stomacher-400 mixer. The DNA was extracted from stool using the QiAamp DNA Mini Kit (QIAGEN, Barcelona, Spain) as indicated by the manufacturer, with the exception that the samples were mixed with the lysis buffer and incubated at a temperature of 95 °C instead of 70 °C to ensure the lysis of Gram-positive and negative bacteria. DNA quantification was carried out by the NanoDrop ND-1000 spectrophotometer (Thermo Fisher Scientific, DE, United States). The extracted DNA was amplified by PCR using primers targeting the targets flanking the variable regions of 1 to 3 of the bacterial gene 16S rRNA (V1-3), subsequently gel-purified, and analyzed using the technology of Roche 454 GS FLX (Branford, CT, United States), being the final amplicon obtained is a 600 pb sequence belonging to the variable region V1-V3 of the 16S rRNA gene. PCR was performed in a total volume of 15 μL for each sample, which contains the forward universal primers 27F and Bif16S-F (10 μmol/L) in a ratio of 9:1 respectively, and the universal barcode 534R as primer inverse (10 μmol/L), in addition to the mixture of dNTP (10 mmol/L), FastStart 10 × buffer with 18 mmol/L of MgCl\textsubscript{2}, FastStartHiFi polymerase (5 U/mL), and 2 μL of genomic DNA. PCR were performed in a high fidelity thermocycler (Roche AppliedScience, Penzberg, Germany). PCR conditions were the following: 95 °C for 2 min, 30 cycles of 95 °C for 20 s, 56 °C for 30 s, and 72 °C for 5 min and a final stage at 4 °C. PCR products were purified using magnetic beadsAMPure XP (Beckman-Coulter, Brea, CA, United States).

DNA quality and concentration were measured using the Quant-ITTM PicoGreen\textsuperscript{a} dsDNAAssay Kit (ThermoFisher, Waltham, MA, United States). Finally, the amplicons are combined in equimolar ratios to create a pool of DNA (109 DNA molecules) that was used for clonal amplification (emPCR) and pyrosequencing according to the manufacturer’s instructions. At the end of the massive sequencing process, all the sequences were annotated according to quality, and the sequences with poor quality and short fragments were eliminated.

Sequences were selected to estimate the total diversity of bacteria in the DNA of the samples. For this purpose, bar codes, primers, chimeras, plasmids, mitochondrial DNA, any sequence not belonging to 16S RNA and sequences < 150 bp were eliminated. For the analysis of all the sequences the MG-RAST server (metagenomic analysis server) was used with the database Ribosomal Project (RDP), which converted the total se-
Dysbiosis and miRNAs in CD

quences into relative abundances of microorganisms of the different taxonomic levels. Processing in MG-RAST includes demultiplexing, quality filtering, length filtering, dereplication and deletion of model organism sequences.

miRNA screening
Total RNA was extracted using the mirVana™ miRNA Isolation Kit, with phenol (ThermoFisher Scientific, MA, United States). The commercially available Kit RT2 miRNA PCR Array System (SA Biosciences-Qiagen, Hilde, Germany) was used for the relative quantification of the 88 most expressed miRNAs following the manufacturer’s instructions. Individual miRNA gene expression was measured by retrotranscription with the miScript II RT Kit (Qiagen, Hilde, Germany), and a quantitative PCR by the miScript SYBR® Green PCR Kit (Qiagen, Hilde, Germany) by a Stratagene 3005 MxP thermocycler.

Statistical analysis
The MG-RAST output file was analyzed with the SPSS Statistics 20.0 software (SPSS Inc), while the STAMP software version 2.1.3 was used for the metagenomic analysis and IMG/M. The Shannon index, based on species richness (number of species present) and species abundance (number of individuals per species), was calculated for control samples and samples with CD. The differences between the two groups were compared using the Mann-Whitney U test. Statistical analysis was performed using the GraphPad Prism 7 and SPSS 20.0 software. Differences between means were performed with significance tests using an analysis of variance (ANOVA) and post-hoc test with less significance. Non-parametric data were expressed as median (range) and analyzed using the Mann-Whitney U test. Differences between proportions were analyzed by chi-square test. Significance was accepted at P < 0.05.

RESULTS

Ecological analysis
Microbial community was characterized using 16S rRNA gene sequencing in 29 samples (n = 13 CD participants and n = 16 healthy controls). The mean Shannon diversity was found higher in the healthy control population compared to the CD group (5.5 vs 3.7), indicating that there is less biodiversity in the structure of microbial communities in CD. To check this, we decided to measure the number of species in both groups (357 control group vs 289 CD group), which showed a decreased number of species in the CD group.

Dysbiosis was observed in CD due to an increased population of Bacteroidetes and reductions in Firmicutes. Firmicutes/Bacteroidetes ratio was 1.71 in controls versus 0.80 in CD. Furthermore, the number of readings obtained using 16S massive sequencing is shown in Figure 1A. 77143 readings were obtained in control samples and 69296 reads in CD group.

Metagenomic analysis
To assess how the intestinal microbial community was distributed in both groups, principal components analysis (PcoA) was performed (Figure 1B). A grouping pattern was identified for most of the subjects in both groups, showing a marked difference between control samples (blue) and CD samples (green). A PERMANOVA calculated by FIRST showed statistically significant differences between groups (P < 0.05).

Analysis in bacterial taxonomic groups
Differential distributions in taxonomic categories were analyzed. Significant differences in Clostridia class were found in the analysis, being decreased in the CD group (Figure 2). Significant differences were found in Entomoplasmataceae (P = 0.001), Bacteriaceae (P = 0.002), Lachnospiraceae (P < 0.0001), Ruminococcaceae (P < 0.0001) and Rikenellaceae (P = 0.003) (Figure 3).

Relative abundance of the most abundant bacterial genera
Significant differences in Ruminococcus (P < 0.001), Roseburia (P = 0.002), Parabacteroides (P = 0.02), Mesoplasma (P = 0.003), Faecalibacterium (P < 0.001), Eubacterium (P = 0.003) and Alitipes (P < 0.003) were observed, showing a decreased distribution in the EC group (Figure 4).

When relative abundance of each bacterial taxon was analyzed, all of them were increased in the control group EC except Clostridium bolteae, only present in CD while absent in the control group: Ruminococcus albus (P = 0.004), Roseburia inulinivorans (P = 0.016), Mesoplasma lactueae (P = 0.002), Faecalibacterium prausnitzii (P < 0.0001), Eubacterium ramulus (P = 0.006), Eubacterium eligens (P = 0.03), Eubacterium coprostanoligenes (P = 0.002), Dialister inis (P = 0.005), Desulfovautotrophicus (P = 0.01), Clostridium cultura spenrichment clone 7-25 (P < 0.0001), Clostridium bolteae (P = 0.04), Clostridia leisenmonsp. BVAB3 (P = 0.02), Butyrivibrio fibrisolvens (P = 0.04), butyrate producing bacterium ART55 / 1 (P = 0.006), Bacteroides dorei (P = 0.04), Alitipes putredinis (P = 0.03), Alitipes finegoldii (P = 0.02).

Functional analysis
A functional metabolic study of the microbiota was performed by comparison between both groups. We observed significant differences in the following functions: Biosynthesis and glycan metabolism, carbohydrate metabolism, lipid metabolism, catabolism, digestive system, amino acid metabolism, immune system. In the CD group, we observed a lower metabolism of carbohydrates (P = 0.000) while the metabolism of lipids was increased in this group (P = 0.000). Data is shown on Figure 5.

miRNAs
In order to analyze the miRNA profile in patients with CD, we performed an array of the 88 most abundant miRNAs in human inflammatory processes. After RNA extraction from biopsies, samples were pooled (control vs affected mucosa). In this analysis, 4 miRNAs were found to be significantly induced (fold change > 1.5) in affected
mucosa vs non-affected: miR-144, miR-211, miR-373-3p and miR-519.

An individual analysis was performed on 10 additional samples from patients with CD, as a validation analysis, where three of them were also found induced (miR-144, miR-211 and miR-519). Results are shown on Figure 6.

DISCUSSION

In this study, we have found a shift in microbial gut community composition that supports dysbiosis in CD patients. The greatest interest of our work is that we have only included new-onset adult CD patients.
Rojas-Feria M et al. Dysbiosis and miRNAs in CD

![Figure 2](image_url)

**Figure 2** Box plot showing a significant difference in the *Clostridia* class between control group (blue) and Crohn’s disease (green).

No confounders of drug therapy, surgery or duration of the disease were present. We described a low proportion of *Firmicutes* population, and a reduction in *Firmicutes/Bacteroidetes* ratio in CD, respect to control samples. In healthy adults, 80% of the identified faecal microbiota belongs to 3 dominant phyla: *Bacteroidetes*, *Firmicutes* (principally *clostridia*) and *Actinobacteria*. *Firmicutes* are considered beneficial and *Bacteroidetes* are considered aggressive, being implicated in the pathogenesis of IBD. The *Firmicutes* to *Bacteroidetes* ratio has shown to be of significant relevance in gut microbiota composition, as an expression of the degree of dysbiosis. In healthy adults, ratios of 10.9 were measured, although ratios between 1 and 5.5 were considered optimum. In our population, the ratio was 1.71 in controls vs 0.8 in CD.

Our results are in concordance with data from other authors, although some of them analysed mucosa microbiota instead of faecal microbiota. Interestingly, in a former study, the reduction in the *Firmicutes/Bacteroidetes* ratio was more likely to be observed in ulcerated mucosa than in non-ulcerated mucosa. Based on this, it is questionable whether the dysbiosis is not an effect instead of a cause. However, these findings have not been confirmed in later studies.

We have also found less biodiversity and a significantly different pattern on microbiota distribution in active CD patients compared to controls. *Ruminococcus*, *Roseburia*, *Parabacteroides*, *Mesoplasmata*, *Faecalibacterium*, *Eubacterium* and *Alistipes* were significantly decreased in our CD cohort. Certain bacteria, including *Bacteroides*, *Bifidobacterium*, *Clostridium* clusters XIVa and IVa, *Eubacterium rectale*, *Faecalibacterium prausnitzii*, lactic acid bacteria, *Roseburia intestinalis*, and others, are closely related to gastrointestinal tract fitness. Therefore, a decrease of these genera could favour the development of CD.

We have described significant differences in *Clostridia* class in the analysis, being decreased in the CD group. This finding is in agreement with other researchers that have identified 43 species of *Firmicutes* in healthy human gut microbial communities, while only 13 species were found in patients with CD. In addition, the proportion of *Clostridium prausnitzii* in CD patients was significantly lower compared to controls. *Clostridium* species have been shown to induce the expansion of Treg cells, reducing intestinal inflammation. *Faecalibacterium* genera may protect the host from mucosal inflammation through several mechanisms, including down-regulation of inflammatory cytokines or IL-10 stimulation, an anti-inflammatory cytokine. *Faecalibacterium prausnitzii*, a proposed member of the microbiota with anti-inflammatory properties, is under-represented in IBD, as we have reported in this study.

*Clostridium boltae* is only present in the CD group. Therefore, this organism could be a target in CD patients as a risk factor for disease development. Despite promising correlations between shifts in microbial composition and CD, the presence or absence of a single taxon has not been identified as causal or protective against the development of disease. This supports the view that compositional change (dysbiosis), rather than a single putative organism, may be responsible for this disease.

Mucosal-associated microbes are uniquely positioned to influence the immune system; particularly, the porous mucus layer in the ileum has been shown to educate the immune system to develop tolerance towards commensals. In fact, faecal microbial transplant (FMT) has been proposed as a potential therapeutic option for individuals with CD based on the hypothesis that changes in dysbiosis could lessen intestinal inflammation.

Besides the shifts in microbiota composition, we have identified significant changes in carbohydrate and lipid metabolism, the first being reduced and the second being heightened. Changes in microbial function between healthy controls and IBD appear more extensive and more consistent compared with changes in community structure. Clostridium cluster XIV (Eubacterium rectale) and Clostridium cluster XIV (Clostridium leptum group and Faecalibacterium prausnitzii) have a function in carbohydrate fermentation and short chain fatty acid (SCFA) production, particularly butyrate. SCFA are the major source of energy for the gut epithelial cells and possess an anti-inflammatory activity. Butyrate has been found to decrease TNF production and proinflammatory cytokine expression in intestinal tissue in patients with CD. Taking all this into account, dysbiosis leads to changes in microbiota metabolism, resulting in a permanent inflammation process for gut cells.

To find a biomarker of active CD, miRNAs expression in gut mucosa was analyzed. We have identified differential expression of 3 miRNAs in affected colonic mucosa from patients with naive CD. These miRNAs (miR-144-3p; miR-211-5p; miR-519d-3p) are induced in the diseased colonic mucosa compared to the healthy areas. The miRNAs identified in our study have not been previously described elsewhere, although multiple different miRNAs expression profile have already been identified in inflamed and non-inflamed mucosa in...
IBD patients. Some studies have demonstrated up-regulation of miRNAs in inflamed mucosa\(^\text{[30]}\) whereas others pointed out down-regulation of miRNA in affected mucosa\(^\text{[31,32]}\). It has been shown that miR-215 expression in biopsies of CD patients correlates with the likelihood of disease progression\(^\text{[10]}\). Nevertheless, the miRNA expression profile in colonic tissue has not been defined yet. Recently, 100 miRNAs have been identified as significantly deregulated between the inflamed and normal mucosa of ascending colon\(^\text{[33]}\). Differentially
expressed miRNAs identified from these studies and our results may be due to differing factors such as sample size, CD patient characteristics (age, drug history, with or without surgery, etc.) and subject population demographics.

It should be noted that although in all our patients we found significant over-expression of these miRNAs, depending on the patient studied we found one of these increased with respect to the others. Therefore, we hypothesized that the combined analysis of specific miRNAs (in our case, miR144-3p; miR-211-5p; miR-519d-3p) could be useful to determine disease proba-
bility indexes in patients. This idea of miRNA combination analysis has already been proposed in other recent studies\(^2\). However, the development of a model including miRNAs combination is still pending.

Although our patient cohort is small, we have carefully selected these patients at the time of diagnosis and all of them had inflammatory phenotype and were naive for treatments. To validate our findings, we will analyze circulating miRNAs, as potential non-invasive biomarkers for diagnosis and disease progression. Some studies have already pointed out this role after infliximab therapy\(^3\) or exclusive enteral nutrition\(^3\).

In conclusion, we found that active non-treated CD patients had a low Firmicutes/Bacteroidetes ratio, less biodiversity in the structure of microbial communities and a significantly different pattern on gut microbiota distribution. Moreover, microbiota metabolism was altered in CD patients compared to healthy subjects. This data strongly suggests that dysbiosis may play a role in the pathogenesis of CD. Three miRNAs have been found induced in affected mucosa vs non-affected mucosa in CD, indicating that the miRNA profile may serve as a biomarker for active disease. Nevertheless, additional studies are needed to identify causative roles for the microbiota and to establish the role of miRNAs in the pathogenesis or diagnosis of IBD.

**ARTICLE HIGHLIGHTS**

**Research background**
Pathogenesis of inflammatory bowel disease (IBD) has not been clarified yet. The gut microbiota plays a key role in the maintenance of intestinal homeostasis and the development and activation of the host immune system. The causality between IBD and alterations in microbiota remains incompletely understood but one theory is that altered microbiota composition and function in IBD result in increased immune stimulation or enhanced mucosal permeability. On the other hand, microRNAs (miRNAs) have been involved in the pathogenesis of IBD and have been explored as biomarkers and therapeutic targets. It has been shown that miRNAs regulate specific genes associated with Crohn’s disease (CD).

**Research motivation and objectives**
Identification of host and microbiota alterations in individual patients should lead to selective target interventions. In this study, we first analyzed the faecal microbiota composition in CD patients at the time of diagnosis. Secondly, we compared miRNA expression in CD gut samples obtained from endoscopically normal and affected mucosa, in order to find a marker of active IBD.

**Research methods**
In this study, we will use deep-sequencing methods to analyze the microbiota from CD patients and control patients. Moreover, a miRNAs screening will be performed to identify individual miRNA involved in inflammation process that could serve as biomarkers for disease progression on therapeutic target.

**Research results**
We found significant differences in microbiota composition when comparing patients with CD compared to the control population. The major differences were found in microbial biodiversity (Shannon Index). We also found a reduction in Firmicutes and an increase in Bacteroidetes. Clostridia class was also significantly reduced in Crohn’s disease group.

**Research conclusions**
We found that active non-treated CD patients had a low Firmicutes/Bacteroidetes ratio, less biodiversity in the structure of microbial communities and a significantly different pattern on gut microbiota distribution. Moreover, microbiota metabolism was altered in CD patients compared to healthy subjects. This data strongly suggests that dysbiosis may play a role in the pathogenesis of CD. Three miRNAs have been found induced in affected mucosa vs non-affected mucosa in CD, indicating that miRNA profile may serve as a biomarker for active disease.

**Research perspectives**
Additional studies are needed to validate the results obtained and to identify causative roles for the microbiota. The role of miRNAs in the pathogenesis or diagnosis of IBD, including CD must be established through deeper analysis and validation in circulating tissues.

**ACKNOWLEDGMENTS**
Dr. María Rojas is supported by Consejería de Salud y Bienestar Social, Junta de Andalucía #PI-0127-2013; this work is also co-funded by European Union (ERDF/ ESF, “Investing in your future”). Dr. JA Del Campo is supported by Nicolás Monardes Program from Servicio Andaluz de Salud (SAS).

**REFERENCES**
1. Xavier RJ, Podolsky DK. Unravelling the pathogenesis of inflammatory bowel disease. Nature 2007; 448: 427-434 [PMID: 17653185 DOI: 10.1038/nature06005]
2. McGovern DP, Kugathasan S, Cho JH. Genetics of Inflammatory Bowel Diseases. Gastroenterology 2015; 149: 1163-1176.e2 [PMID: 26255561 DOI: 10.1053/j.gastro.2015.08.001]
3. Anderson CA, Boucher G, Lees CW, Franke A, D’Amato M, Taylor KD, Lee JC, Goyette P, Imelimiok M, Latino A, Lagacé C, Scott R, Ammarnejad L, Bumpstead S, Baidoo L, Baldassano RN, Barclay M, Bayless TM, Brand S, Bünning C, Colombel JF, Denson LA, De Vos M, Dubinsky M, Edwards C, Ellinghaus D, Fehrmann RS, Floyd JA, Florin T, Franchimont D, Franke L, Georges M, Glas J, Glazer NL, Guthery SL, Haritunians T, Hayward NK, Huot J, Jobin G, Laukens D, Lawrance I, Lémann M, Levine A, Liiboutille C, Louis E, McGovern DP, Milla M, Montgomery GW, Morley KI, Mowat C, Ng A, Newman W, Ophoff RA, Papa L, Palmeri O, Peyrin-Biroulet L, Panis J, Phillips A, Prescott NJ, Proctor DD, Roberts R, Russell R, Rutgeerts P, Sanderson J, Sans M, Schumann P, Seibold F, Sharrar Y, Simon LA, Seielstad M, Steinhardt AH, Targan SR, van den Borg LH, Vatn M, Verspaget H, Walters T, Wijmenga C, Wilson DC, Westra HJ, Xavier J, Zhao ZZ, Ponsioen CY, Andersen V, Torkvist L, Goumelou M, Anagnostou NP, Karlsson TH, Kupcinys L, Sventoraityte J, Mansfield JC, Kugathasan S, Silverberg MS, Halfvarson J, Rotger JL, Mathew CG, Griffiths AM, Geary R, Ahmad T, Brant SR, Chamailliard M, Satsangi J, Cho JH. Genetics of Inflammatory Bowel Diseases. Nature 2007; 448: 427-434 [PMID: 17653185 DOI: 10.1038/nature06005]
4. Franke A, McGovern DP, Barrett JC, Wang K, Radford-Smith GL, Ahmad T, Lees CW, Balschun T, Lee J, Roberts R, Anderson CA, Bis JC, Bumpstead S, Ellinghaus D, Festen EM, Georges M, Green T, Haritunians T, Justins L, Latino A, Mathew CG, Montgomery GW, Prescott NJ, Raychaudhuri S, Rotger JL, Schumann P, Sharma Y, Simmons LA, Taylor KD, Whitman D, Wijmenga C, Baldassano RN, Barclay M, Bayless TM, Brand S, Bünning C, Cohen A, Colombel JF, Cottone M, Stronati L, Denson T, De Vos M, D’Inca R, Dubinsky M, Edwards C, Florin T, Franchimont D, Geary R, Glas J, Van Gossum A, Guthery SL, Halfvarson J, Verspaget HW, Huot J, Karban A, Laukens D, Lawrance I, Lemann M, Levine A, Liiboutille C, Louis E, Mowat C, Newman W, Panis J, Phillips A, Proctor DD, Regueiro M, Russell R, Rutgeerts P, Sanderson J,
Suns M, Seibold F, Steinhardt AH, Stokkers PC, Torkilst V, Luklak-Ublic G, Wilson D, Wallers T, Tangan SR, Brant SR, Rioux JD, D'Amato M, Weersma RK, Kugathasan S, Griffiths AM, Mansfield JC, Vermeire S, Duer R, Silverberg MS, Satsangi J, Schreiber S, Cho JH, Ananda V, Hakonarson H, Daly MJ, Parkes M. Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci. Nat Genet 2010; 42: 1118-1125 [PMID: 21020463 DOI: 10.1038/ng.717]

Khor B, Gardet A, Xavier RJ. Genetics and pathogenesis of inflammatory bowel disease. Nature 2011; 474: 307-317 [PMID: 21677747 DOI: 10.1038/nature10209]

Schafer JS. MicroRNAs: how many in inflammatory bowel disease? Curr Opin Gastroenterol 2013; 32: 258-266 [PMID: 27138057 DOI: 10.1097/MOG.0b013e32830000a8]

Wu F, Zikoska M, Trindade A, Dassopoulos T, Harris MR, Bayless TM, Brant SR, Chakravarti S, Kwon JH. MicroRNAs are differentially expressed in ulcerative colitis and alter expression of macrophage inflammatory peptide-2 alpha. Gastroenterology 2008; 135: 1628-1635.e24 [PMID: 18835337 DOI: 10.1016/j.gastro.2008.07.068]

Schafer JS, Attuim T, Opekun AR, Abraham B, Hou J, Shelby H, Graham DY, Strecklaus K, Klein JR. MicroRNA signatures differentiate Crohn’s disease from ulcerative colitis. BMC Immunol 2013; 16: 5 [PMID: 25886994 DOI: 10.1186/1471-2178-14-5]

Cao B, Zhou X, Ma J, Zhou W, Yang W, Fan D, Hong L. Role of MiRNAs in Inflammatory Bowel Disease. Dig Dis Sci 2017; 62: 1426-1438 [PMID: 28391412 DOI: 10.1007/s10620-017-4567-1]

Peck BC, Weiser M, Lee SE, Gipsom GR, Iyer VB, Sartor RB, Hao Y, Matsumoto JS, Siskind C, Trembath RG, Rabar S, Sadiq TS, Furey TS, Sethupathy P, Sheikh ZZ. MicroRNAs Classify Different Disease Behavior Phenotypes of Crohn’s Disease and May Have Prognostic Utility. Inflamm Bowel Dis 2015; 21: 2178-2187 [PMID: 26164662 DOI: 10.1097/MIB.0000000000000478]

Eckburg PB, Bik EM, Bernstein CN, Purdom E, Dethlefsen L, Sargent M, Gill SR, Nelson KE, Relman DA. Diversity of the human intestinal microbial flora. Science 2005; 308: 1655-1658 [PMID: 15831718 DOI: 10.1126/science.1150160]

Lay C, Sutren M, Rochet V, Saunier K, Doré J, Rigottier-Gois L. Design and validation of 16S rRNA probes to enumerate members of the Clostridium leptum subgroup in human faecal microbiota. Environ Microbiol 2005; 7: 933-946 [PMID: 15496290 DOI: 10.1111/j.1462-2920.2005.00763.x]

Bloom SM, Bik AJ, Nishihara R, Copps P, Pigneur B, Watterlot L, Godon JJ, Turnbaugh PJ, Klein S, Gordon JI. Microbial ecology: features of the gastrointestinal microbiome and their effects on human health. Science 2013; 342: 447-453 [PMID: 24072822 DOI: 10.1126/science.1237910]

San M, BNORMALIC L, Wallen AC, Bornstein VC, Shan K, He B, Casis L, Biga A, Cols M, Commera L, Huang B, Blander JM, Xiong H, Mayer L, Berin C, Augenlicht LH, Velcich A, Cerutti Y, Aucoumea M, Bierut A. The microbiome of inflammatory bowel disease. Gut 2015; 64: 2167-2177 [PMID: 25647155 DOI: 10.1136/gutjnl-2014-307524]

Morgan XC, Tickle TL, Wolfs LF, Gevers D, Deveney KL, Ward DV, Reyes JA, Shah SA, LeLeiko N, Snapper SB, Bouzavars A, Horoski J, Deschamps BE, Xavier RJ, Huttenhower C. Dysfunction of the intestinal microbiome in inflammatory bowel disease and treatment. Genome Biol 2012; 13: R79 [PMID: 23013615 DOI: 10.1186/gb-2012-13-9-r79]

Segain JP, Raising de la Blandière D, Bourreille A, Leray V, Gervois N, Rosales C, Ferrier L, Bonnet C, Blottière HM, Galmiche JP. Butyrate inhibits inflammatory responses through NFκB inhibition: implications for Crohn’s disease. Inflamm Bowel Dis 2015; 21: 1219-1228 [PMID: 25844309 DOI: 10.1097/MIB.0000000000000382]

Wright EK, Kanma MA, Teo SM, Ionou M, Wagner J, Kirkwood CD. Recent advances in characterizing the gastrointestinal microbiome in Crohn's disease: a systematic review. Inflamm Bowel Dis 2015; 21: 1219-1228 [PMID: 25844309 DOI: 10.1097/MIB.0000000000000382]

Shan M, Gentile M, Weiser JR, Wallen AC, Bornstein VC, Shan K, He B, Casis L, Biga A, Cols M, Commera L, Huang B, Blander JM, Xiong H, Mayer L, Berin C, Augenlicht LH, Velcich A, Cerutti Y, Aucoumea M, Bierut A. The microbiome of inflammatory bowel disease. Gut 2015; 64: 2167-2177 [PMID: 25647155 DOI: 10.1136/gutjnl-2014-307524]
Nijhuis A, Biancheri P, Lewis A, Bishop CL, Giuffrida P, Chan C, Feakins R, Poulson R, Di Sabatino A, Corazza GR, MacDonald TT, Lindsay JO, Silver AR. In Crohn’s disease fibrosis-reduced expression of the miR-29 family enhances collagen expression in intestinal fibroblasts. *Clin Sci* (Lond) 2014; **127**: 341-350 [PMID: 24641356 DOI: 10.1042/CS20140048]

Wu LY, Ma XP, Shi Y, Bao CH, Jin XM, Lu Y, Zhao JM, Zhou CL, Chen D, Liu HR. Alterations in microRNA expression profiles in inflamed and noninflamed ascending colon mucosae of patients with active Crohn’s disease. *J Gastroenterol Hepatol* 2017; **32**: 1706-1715 [PMID: 28261881 DOI: 10.1111/jgh.13778]

Fujikawa S, Nakamichi I, Esaki M, Asano K, Matsumoto T, Kitazono T. Serum microRNA levels in patients with Crohn’s disease during induction therapy by infliximab. *J Gastroenterol Hepatol* 2014; **29**: 1207-1214 [PMID: 24447044 DOI: 10.1111/jgh.12523]

Guo Z, Gong J, Li Y, Gu L, Cao L, Wang Z, Zhu W, Li J. Mucosal MicroRNAs Expression Profiles before and after Exclusive Enteral Nutrition Therapy in Adult Patients with Crohn’s Disease. *Nutrients* 2016; **8** [PMID: 27556489 DOI: 10.3390/nu8080519]

Rojas-Feria M *et al*. Dysbiosis and miRNAs in CD
